Dr Chari on Findings From the MonumenTAL-1 Trial in Relapsed/Refractory Multiple Myeloma
December 15th 2023Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.
Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.
Responses With Pirtobrutinib Remain High Despite Acquired Resistance in Relapsed CLL/SLL
December 13th 2023Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.
DZD8586 Demonstrates Responses Across Dose Levels in B-Cell Non-Hodgkin Lymphoma
December 13th 2023DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.
Asciminib Elicits Safe and Durable Responses in Previously Treated CML
Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.
Tafasitamab Quadruplet Shows Efficacy in Newly Diagnosed DLBCL
December 12th 2023The use of tafasitamab-cxix, lenalidomide, rituximab, and acalabrutinib in the first-line setting induced high responses in patients with newly diagnosed diffuse large B-cell lymphoma, with responders deriving benefit from subsequent treatment with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Pirtobrutinib Displays Activity in Relapsed/Refractory MCL Following Covalent BTK Inhibitor Therapy
Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.
BGB-16673 Delivers Responses With a Tolerable Safety Profile Across R/R B-Cell Malignancies
December 12th 2023The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.
D-VRd Improves PFS in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
December 12th 2023Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant, daratumumab, bortezomib, lenalidomide, and dexamethasone consolidation and daratumumab/lenalidomide maintenance prolonged progression-free survival in patients with newly diagnosed, transplant-eligible multiple myeloma.
Ibrutinib Plus Venetoclax Confers PFS, Response Benefit in Relapsed/Refractory MCL
Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival vs ibrutinib plus placebo in patients with relapsed/refractory MCL.
Financial Navigation Program May Alleviate Cost Burden Associated With Multiple Myeloma
December 12th 2023Utilization of a financial navigation program is feasible for reducing cost burden and improving quality of life in patients with multiple myeloma who are more likely to experience financial toxicity and have difficulty accessing appropriate resources and support services.
NX-2127 Elicits Responses With Manageable Safety in Heavily Pretreated B-cell Malignancies
December 12th 2023NX-2127 showcased early efficacy in the form of responses with an acceptable toxicity profile in patients with relapsed or refractory B-cell malignancies, according to data from the ongoing phase 1 NX-2127-001 trial.
Dr Andorsky on Real-World Treatment Patterns With BTK Inhibitors in CLL/SLL
December 12th 2023David J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.
Zanubrutinib Triplet Shows Early Promise in Treatment-Naive TP53-Mutant MCL
December 11th 2023The combination comprised of zanubrutinib, obinutuzumab, and venetoclax elicited high response rates and 2-year progression-free survival rates that compared favorably with historical outcomes achieved with chemoimmunotherapy in high-risk patients with previously untreated mantle cell lymphoma harboring TP53 mutations.
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis
Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor–naive myelofibrosis.
Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma
December 11th 2023Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.